08.06.15
Catalent has formed an advisory board to strategically shape growth of the company’s biologics business.
Founding members of the advisory board are Carolyn Bertozzi, Barry Buckland, Michael Buckley, Daniel Marshak and Edward Robinson.
“This new board brings diverse expertise in biologics development and commercialization, new technologies, contract services and a deep understanding of the key challenges facing biologics developers, both now and in the future,” said Mike Riley, vice president and general manager, Catalent Biologics. “Catalent Biologics has developed a unique combination of proprietary technology platforms and integrated services to enable our partners’ next generation of biologics treatments. These expert advisors will play a key role in guiding our strategy as we continue to build our biopharma solutions offerings.”
Carolyn Bertozzi, Ph.D., is the Anne T. and Robert M. Bass professor of chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi is the recipient of numerous honors and awards for her research, including a MacArthur Foundation Fellowship and was the first woman awarded the Lemelson-MIT award for inventors. She is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. She co-founded Redwood Bioscience, which was acquired by Catalent in 2014, and currently serves as the Chair of Redwood’s Scientific Advisory Board.
Barry Buckland, Ph.D., spent approximately 30 years at Merck & Co., most recently as vice president and head of the Bioprocess R&D organization at Merck Research Laboratories and was involved in the development and launch of key products including Recombivax HB and Gardasil. Dr. Buckland is a member of the National Academy of Engineering, and is the recipient of numerous awards including PhRMA ’s Discoverers Award for the development of Gardasil and the American Chemical Society’s Marvin Johnson Award for Lifetime Achievement in Biotechnology .
Michael Buckley, Ph.D., has over 30 years of experience in the biotech industry, most recently serving as vice president of core technology and vice president of process sciences at Takeda Pharmaceuticals. Dr. Buckley previously held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, where he was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 Antibody .
Daniel R. Marshak, Ph.D., currently serves as a director on the board of InVivo Therapeutics , a medical device and biotechnology company in Cambridge, MA. He most recently served as senior vice president and chief scientific officer for Perkin Elmer, Inc., and previously served as vice president and chief technology officer, biotechnology, for Cambrex Corporation and senior vice president and chief scientific officer of Osiris Therapeutics where he led stem Cell research from inception to late stage Clinical Trials . Dr. Marshak currently serves on the International Society for Stem Cell Research Global Advisory Council, and recently held an appointment as adjunct associate professor at the Johns Hopkins University School of Medicine.
Edward R. Robinson is currently chairman and chief executive officer of Acadia Harvest, and has over 30 years of experience in the biotech industry. Mr. Robinson previously served as an executive vice president at Cambrex Corporation, president of Solutia Pharmaceutical Services, and president of Lonza Biologics where he tripled the size of the business over a three year period and was instrumental in launching Lonza’s US operations.
Founding members of the advisory board are Carolyn Bertozzi, Barry Buckland, Michael Buckley, Daniel Marshak and Edward Robinson.
“This new board brings diverse expertise in biologics development and commercialization, new technologies, contract services and a deep understanding of the key challenges facing biologics developers, both now and in the future,” said Mike Riley, vice president and general manager, Catalent Biologics. “Catalent Biologics has developed a unique combination of proprietary technology platforms and integrated services to enable our partners’ next generation of biologics treatments. These expert advisors will play a key role in guiding our strategy as we continue to build our biopharma solutions offerings.”
Carolyn Bertozzi, Ph.D., is the Anne T. and Robert M. Bass professor of chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi is the recipient of numerous honors and awards for her research, including a MacArthur Foundation Fellowship and was the first woman awarded the Lemelson-MIT award for inventors. She is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. She co-founded Redwood Bioscience, which was acquired by Catalent in 2014, and currently serves as the Chair of Redwood’s Scientific Advisory Board.
Barry Buckland, Ph.D., spent approximately 30 years at Merck & Co., most recently as vice president and head of the Bioprocess R&D organization at Merck Research Laboratories and was involved in the development and launch of key products including Recombivax HB and Gardasil. Dr. Buckland is a member of the National Academy of Engineering, and is the recipient of numerous awards including PhRMA ’s Discoverers Award for the development of Gardasil and the American Chemical Society’s Marvin Johnson Award for Lifetime Achievement in Biotechnology .
Michael Buckley, Ph.D., has over 30 years of experience in the biotech industry, most recently serving as vice president of core technology and vice president of process sciences at Takeda Pharmaceuticals. Dr. Buckley previously held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, where he was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 Antibody .
Daniel R. Marshak, Ph.D., currently serves as a director on the board of InVivo Therapeutics , a medical device and biotechnology company in Cambridge, MA. He most recently served as senior vice president and chief scientific officer for Perkin Elmer, Inc., and previously served as vice president and chief technology officer, biotechnology, for Cambrex Corporation and senior vice president and chief scientific officer of Osiris Therapeutics where he led stem Cell research from inception to late stage Clinical Trials . Dr. Marshak currently serves on the International Society for Stem Cell Research Global Advisory Council, and recently held an appointment as adjunct associate professor at the Johns Hopkins University School of Medicine.
Edward R. Robinson is currently chairman and chief executive officer of Acadia Harvest, and has over 30 years of experience in the biotech industry. Mr. Robinson previously served as an executive vice president at Cambrex Corporation, president of Solutia Pharmaceutical Services, and president of Lonza Biologics where he tripled the size of the business over a three year period and was instrumental in launching Lonza’s US operations.
